Picture loading failed.

Anti-IL21 therapeutic antibody (Pre-made Avizakimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Avizakimab (formerly BOS 161721) is a fully human anti-interleukin 21 monoclonal antibody, being developed by Boston Pharmaceuticals, for treatment of autoimmune disorders including systemic lupus erythematosus.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-041-1mg 1mg 3090
GMP-Bios-ab-041-10mg 10mg 21890
GMP-Bios-ab-041-100mg 100mg 148000
GMP-Bios-ab-041-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-IL21 therapeutic antibody (Pre-made Avizakimab biosimilar,Whole mAb)
INN Name Avizakimab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesMedImmune;Boston Pharmaceuticals
Conditions Approvedna
Conditions ActiveSystemic lupus erythematosus
Conditions DiscontinuedAutoimmune disorders
Development Techna